Low Dose Naltrexone: What It Is and When It Helps

Low Dose Naltrexone (LDN) is an off-label, low-dose use of naltrexone, a generic medication that is FDA-approved at 50 mg for opioid and alcohol dependence. LDN has been studied in small trials for conditions such as fibromyalgia and some autoimmune and chronic pain conditions, but it is not FDA-approved for any of them, and the evidence is still limited.

This article walks through what LDN actually is, how it works, what conditions it has been studied for, and what to realistically expect. The goal is to give you the foundation to have an informed conversation with a prescribing provider — not to replace that conversation.

What naltrexone is, in its standard form

Naltrexone is an opioid receptor antagonist developed in the 1960s; naltrexone tablets were FDA-approved in 1984 for the treatment of opioid use disorder and later alcohol dependence. The standard dose is 50 mg daily. At this dose, naltrexone fully blocks opioid receptors, which prevents the rewarding effects of opioids and reduces alcohol cravings. It has decades of safety data at the standard dose and is widely used in addiction medicine.

The story of Low Dose Naltrexone begins in the 1980s with Dr. Bernard Bihari, a New York physician working with HIV patients before effective antiretroviral therapy existed. Bihari reported observations with low doses of naltrexone — well below the FDA-approved 50 mg — in his patients, and later in autoimmune disease, multiple sclerosis, and chronic pain conditions. These were uncontrolled clinical observations, not controlled trials.

How LDN works mechanistically

The mechanism of LDN is genuinely different from standard naltrexone, and it is still being studied.

At low doses, naltrexone briefly blocks opioid receptors for several hours. The body responds to this blockade by upregulating production of endogenous opioids — particularly beta-endorphin and met-enkephalin. By the time the blockade wears off (which it does within hours at low doses), the body has produced more endogenous opioids than it had before. The net effect is a sustained increase in endogenous opioid signaling.

This increase has multiple downstream effects. Endogenous opioids modulate immune function — particularly T-cell balance and natural killer cell activity. They affect mood and pain perception. They appear to influence inflammatory cytokine production.

The second key mechanism is microglial modulation. Microglia are the immune cells of the central nervous system, and chronic microglial activation contributes to neuroinflammation in many conditions: fibromyalgia, chronic pain syndromes, multiple sclerosis, complex regional pain syndrome, and increasingly recognized in long COVID and post-viral syndromes. LDN appears to dampen pathological microglial activation through Toll-like receptor 4 antagonism — a pathway distinct from its opioid receptor effects.

These proposed mechanisms come mainly from laboratory research and have not been confirmed as the basis for any clinical benefit in people.

Conditions LDN has been studied for

The evidence base for LDN is heterogeneous across conditions. Some have been studied in small randomized trials; others only in case reports or small uncontrolled studies. LDN is not FDA-approved for any of the conditions below; its use for them is off-label. The honest picture:

Fibromyalgia. Several small randomized trials have studied LDN for fibromyalgia, with mixed results. Benefit has not been established in large trials.

Inflammatory bowel disease (Crohn’s and ulcerative colitis). Small studies have examined LDN as an add-on to conventional IBD therapy; the evidence is limited. It is not a replacement for conventional IBD therapy.

Multiple sclerosis. Studies are mixed, and LDN has not been shown to change the course of MS. It is not a substitute for disease-modifying therapy.

Hashimoto’s thyroiditis. The evidence is limited to small studies; benefit has not been established.

Chronic fatigue syndrome / ME-CFS. Only small studies exist; benefit has not been established.

Long COVID and post-viral syndromes. Small studies are under way; benefit has not been established. This is a fast-evolving area.

Complex regional pain syndrome (CRPS). Evidence is limited to case reports and small studies.

Other autoimmune conditions. Lupus, rheumatoid arthritis, psoriasis, ankylosing spondylitis, and others have smaller evidence bases but reasonable mechanistic rationale. Use as complement to specialist-directed therapy, not as replacement.

Other chronic pain conditions. Some patients with chronic pain not responsive to standard therapy may benefit from LDN as part of multi-modal pain management.

What LDN does not do

LDN is not a cure for any of these conditions. It is not a substitute for appropriate specialty care in serious autoimmune disease. Some patients report symptom improvement and others do not; individual results vary. Patients should expect realistic outcomes, not miraculous ones.

LDN does not work for everyone, and there is currently no reliable way to predict who will respond.

How LDN is prepared

LDN is taken orally as a compounded preparation, since the standard 50 mg pill is not divisible to the small doses needed. Compounded medications are not FDA-approved.

Dose and timing are set by the prescribing provider and adjusted for tolerability.

Side effects and considerations

Side effects reported with LDN are usually mild. The most common are:

Vivid dreams or sleep disruption in the first 1 to 2 weeks of starting therapy. Often resolves as the body adjusts. Can be addressed with slower titration or earlier dosing.

Mild gastrointestinal upset in some patients during titration. Usually transient.

Headache in a minority of patients during initial weeks.

Severe side effects appear uncommon, but long-term safety at low doses has not been studied in large trials.

Important contraindication: LDN cannot be combined with opioid pain medications. It will block their effect. Patients on chronic opioid therapy must transition off opioids before starting LDN, which requires careful coordination with their pain management physician. Patients who anticipate needing opioid pain medication for surgery should pause LDN appropriately around the procedure.

Other considerations: Caution in significant liver disease (since naltrexone is hepatically metabolized). Pregnancy and breastfeeding are areas where the evidence is limited; we typically defer LDN in those contexts.

Who prescribes LDN

LDN is not commonly prescribed in conventional medicine. Most general practitioners, rheumatologists, and gastroenterologists do not prescribe it — partly because it is off-label, partly because it is not promoted by pharmaceutical companies (it is a generic compounded medication), and partly because it was not part of their training.

Physicians who do prescribe LDN tend to be in functional medicine, integrative medicine, pain medicine, or practices like ours. The LDN Research Trust maintains a directory of prescribing physicians for patients seeking knowledgeable prescribers.

If you are considering LDN, find a prescriber who knows it well and can monitor response and adjust dosing — not a clinic that prescribes it as one of many bundled interventions without specific expertise.

What good LDN care looks like

Quality LDN prescribing involves:

Comprehensive baseline workup — appropriate labs to characterize your underlying condition, rule out competing diagnoses, and establish comparison values for monitoring.

Honest discussion of evidence — what the data actually says about your specific condition, realistic expectations for response, and what non-response would look like.

Standard titration with adjustment based on response — starting low, titrating to therapeutic dose, willing to adjust upward or downward based on tolerability and effect.

Coordination with your specialty care — communication with your rheumatologist, gastroenterologist, or other specialists when relevant. LDN works alongside specialty care, not in place of it.

Structured follow-up — assessment of response at 6 to 12 weeks, willingness to discontinue if no benefit, ongoing monitoring of relevant lab markers and patient-reported outcomes.

Realistic framing — willingness to discuss when LDN is or isn’t working, openness to changing course if needed.

Bottom line

Low Dose Naltrexone is an off-label, low-dose use of a generic medication. The evidence base is limited and varies across conditions, and LDN is not FDA-approved for any of them. The mechanism is still being studied. The cost is low.

For patients with fibromyalgia, autoimmune disease, IBD, chronic pain, long COVID, or related inflammatory conditions who have not responded adequately to standard care, LDN may be discussed as part of an informed conversation with a prescribing provider. It will not work for everyone.